StreetInsider.com News Articles

Eisai and Osaka Prefecture Enter into Collaboration to Promote Awareness of Dementia and Mild Cognitive Impairment (MCI)

Tue, 15 Sep 2026 08:04:00 -0400

TOKYO, Sept 15, 2026 - (JCN Newswire) - - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has entered into an agreement (the "Agreement") with Osaka Prefecture (Governor: Hirofumi Yoshimura) to collaborate on promoting awareness and understanding of dementia and mild cognitive impairment (MCI).

Based on the fundamental principles of Japan's "Basic Act on Dementia to Promote an Inclusive Society", the Agreement aims to promote the development of communities where people living with dementia can continue to live with hope and peace of mind in familiar surroundings. Under the Agreement, Osaka Prefecture and Eisai will

Eisai and Osaka Prefecture Enter into Collaboration to Promote Awareness of Dementia and Mild Cognitive Impairment (MCI)

Tue, 15 Sep 2026 08:04:00 -0400

LEQEMBI IQLIK(R) (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease

Thu, 27 Aug 2026 09:09:00 -0400

TOKYO and CAMBRIDGE, Mass., Aug 27, 2026 - (JCN Newswire) - - Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB, announced today that once weekly lecanemab-irmb subcutaneous injection (brand name: LEQEMBI IQLIK(R))is now available in the U.S. for initiation therapy for early Alzheimer's disease (AD) in adults with mild cognitive impairment (MCI) or mild dementia due to AD, collectively referred to as early AD.

LEQEMBI IQLIK is administered via an autoinjector, introducing a convenient alternative to intravenous (IV) dosing from the start of treatment. For initiation, the approved regimen is 500 mg given once weekly as two consecutive 250 mg

LEQEMBI IQLIK(R) (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease

Thu, 27 Aug 2026 09:09:00 -0400

LEQEMBI IQLIK(R) (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease

Thu, 27 Aug 2026 09:09:00 -0400

LEQEMBI IQLIK(R) (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease

Thu, 27 Aug 2026 09:09:00 -0400

LEQEMBI IQLIK(R) (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease

Thu, 27 Aug 2026 09:09:00 -0400

LEQEMBI IQLIK(R) (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease

Thu, 27 Aug 2026 09:09:00 -0400

LEQEMBI IQLIK(R) (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease

Thu, 27 Aug 2026 09:09:00 -0400

LEQEMBI IQLIK(R) (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease

Thu, 27 Aug 2026 09:09:00 -0400

Pfizer and Eisai Commence Co-promotion of "NURTEC(R)" for the Acute Treatment and Prophylaxis (Preventive Treatment) of Migraine

Mon, 27 Jul 2026 09:50:00 -0400

TOKYO, Jul 27, 2026 - (JCN Newswire) - - Pfizer Japan Inc. (Headquarters: Tokyo, President and Representative Director: Hiroo Igarashi, "Pfizer") and Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the companies will commence the co-promotion of the oral calcitonin gene-related peptide (CGRP) receptor antagonist Nurtec(R) OD Tablet 75mg (generic name: rimegepant sulfate hydrate, hereinafter "Nurtec") in Japan from September 1, 2026.